C4 Therapeutics, Inc.
CCCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $35,584 | $20,756 | $31,096 | $45,785 |
| % Growth | 71.4% | -33.3% | -32.1% | – |
| Cost of Goods Sold | $0 | $7,737 | $0 | $0 |
| Gross Profit | $35,584 | $13,019 | $31,096 | $45,785 |
| % Margin | 100% | 62.7% | 100% | 100% |
| R&D Expenses | $110,637 | $117,706 | $117,841 | $94,665 |
| G&A Expenses | $42,124 | $42,081 | $42,789 | $33,254 |
| SG&A Expenses | $42,124 | $42,081 | $42,789 | $33,254 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2,437 | -$7,737 | $0 | $0 |
| Operating Expenses | $155,198 | $152,050 | $160,630 | $127,919 |
| Operating Income | -$119,614 | -$139,031 | -$129,534 | -$82,134 |
| % Margin | -336.1% | -669.8% | -416.6% | -179.4% |
| Other Income/Exp. Net | $14,429 | $7,818 | $1,359 | -$1,758 |
| Pre-Tax Income | -$105,185 | -$131,213 | -$128,175 | -$83,892 |
| Tax Expense | $131 | $1,280 | $0 | $0 |
| Net Income | -$105,316 | -$132,493 | -$128,175 | -$83,892 |
| % Margin | -296% | -638.3% | -412.2% | -183.2% |
| EPS | -1.52 | -2.67 | -2.62 | -1.82 |
| % Growth | 43.1% | -1.9% | -44% | – |
| EPS Diluted | -1.52 | -2.67 | -2.62 | -1.82 |
| Weighted Avg Shares Out | 69,370 | 49,641 | 48,862 | 46,042 |
| Weighted Avg Shares Out Dil | 69,370 | 49,641 | 48,862 | 46,042 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,429 | $9,812 | $3,575 | $387 |
| Interest Expense | $0 | $1,373 | $2,216 | $2,145 |
| Depreciation & Amortization | $1,818 | $7,737 | $1,676 | $1,492 |
| EBITDA | -$103,367 | -$122,103 | -$124,283 | -$80,255 |
| % Margin | -290.5% | -588.3% | -399.7% | -175.3% |